lomvastomig

{
  "id": "MLC-T-ONC-014877",
  "term": "lomvastomig",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lomvastomig simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.",
  "synonyms": [
    "anti-PD-1 x TIM-3 bispecific antibody RO7121661",
    "anti-PD-1/anti-TIM-3 bispecific antibody RO7121661",
    "anti-PD-1/TIM-3 bispecific antibody RO7121661"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lomvastomig/"
}